| Identification | Back Directory | [Name]
Glycine, N-[(3R,4S)-4-[(3,4-dichlorophenyl)sulfonyl]tetrahydro-1,1-dioxido-3-thienyl]-, rel- | [CAS]
2416095-00-4 | [Synonyms]
CBR-470-2
Glycine, N-[(3R,4S)-4-[(3,4-dichlorophenyl)sulfonyl]tetrahydro-1,1-dioxido-3-thienyl]-, rel- | [Molecular Formula]
C12H13Cl2NO6S2 | [MDL Number]
MFCD32878269 | [MOL File]
2416095-00-4.mol | [Molecular Weight]
402.27 |
| Chemical Properties | Back Directory | [Boiling point ]
734.1±60.0 °C(Predicted) | [density ]
1.71±0.1 g/cm3(Predicted) | [storage temp. ]
4°C, stored under nitrogen | [solubility ]
DMSO: 200 mg/mL (497.18 mM) | [form ]
Solid | [pka]
2.34±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
CBR-470-2, a glycine-substituted analog, can activate NRF2 signaling. CBR-470-2 can be used for the research of modulation glycolysis[1]. | [in vivo]
CBR-470-2 (50 mg/kg; p.o. twice daily for 10 d) induces activation of NRF2 signaling in vivo[1]. | Animal Model: | Balb/C mice (5-week old) are exposed to UVB[1] | | Dosage: | 50 mg/kg | | Administration: | P.o. twice daily for 10 days | | Result: | Resulted in comparable beneficial effects on erythema histological scores and total wounded area.
Decreased epidermal thickness in response to UV exposure.
|
| [References]
[1] Bollong MJ, et, al. A metabolite-derived protein modification integrates glycolysis with KEAP1-NRF2 signalling. Nature. 2018 Oct;562(7728):600-604. DOI:10.1038/s41586-018-0622-0 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|